[ChinaNet Online Holdings Reports Record Second Quarter 2010; Net Income grew 223% to $4.2 Million with Diluted EPS of $0.20 Results underscore significant progress in ChinaNet becoming a leading B2B Internet advertising solutions provider · Revenues increased 28% in the second quarter, driven by an 87% increase in Internet Advertising · Net income grew 223% YOY to $4.2 million, with]
[BIOSTAR PHARMACEUTICALS, INC. SECOND QUARTER REVENUE INCREASED 46.4% TO $19.4 MILLION XIANYANG, China, August 17, 2010 - Q2 2010 revenue increased 46.4% to $19.4 million - Q2 2010 Non-GAAP adjusted net income increased 50.9% to $5.8 million with adjusted EPS of $0.21 - Biostar reiterates guidance for 2010: Revenue expected to be between $80.0 to $82.0 million and net income]
[ChinaNet Online Holdings Reports Record Second Quarter 2010; Net Income grew 223% to $4.2 Million with Diluted EPS of $0.20 Results underscore significant progress in ChinaNet becoming a leading B2B Internet advertising solutions provider · Revenues increased 28% in the second quarter, driven by an 87% increase in Internet Advertising · Net income grew 223% YOY to $4.2 million, with]
[BIOSTAR PHARMACEUTICALS, INC. SECOND QUARTER REVENUE INCREASED 46.4% TO $19.4 MILLION XIANYANG, China, August 17, 2010 - Q2 2010 revenue increased 46.4% to $19.4 million - Q2 2010 Non-GAAP adjusted net income increased 50.9% to $5.8 million with adjusted EPS of $0.21 - Biostar reiterates guidance for 2010: Revenue expected to be between $80.0 to $82.0 million and net income]
[Skystar Bio-Pharmaceutical Reports 33% Growth in Revenue From Continuing Operations in Second Quarter Fiscal Year 2010 Gross Margin Remains of 53%; $0.33 Diluted Earnings Per Share; Company reiterates fiscal 2010 guidance of $45.5 Million to $47.5 Million XI’AN, CHINA – August 17, 2010 -- - Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) ("Skystar" or the "Company"), Second Quarter 2010 Highlights · Revenue increases]
[Skystar Bio-Pharmaceutical Reports 33% Growth in Revenue From Continuing Operations in Second Quarter Fiscal Year 2010 Gross Margin Remains of 53%; $0.33 Diluted Earnings Per Share; Company reiterates fiscal 2010 guidance of $45.5 Million to $47.5 Million XI’AN, CHINA – August 17, 2010 -- - Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) ("Skystar" or the "Company"), Second Quarter 2010 Highlights · Revenue increases]
[China Wind Systems, Reports Second Quarter 2010 Results -- Second quarter 2010 revenuesreased 39.7% to $19.0 million -- Netomereased 69.8% to $3.0 million, or $0.12 per diluted share Press Release CWS News WUXI, Jiangsu, China, Aug. 16 /PRNewswire-Asia-FirstCall/ -- China Wind Systems, (Nasdaq: Second Quarter 2010 Highlights and Recent Events]
[China Wind Systems, Reports Second Quarter 2010 Results -- Second quarter 2010 revenuesreased 39.7% to $19.0 million -- Netomereased 69.8% to $3.0 million, or $0.12 per diluted share Press Release CWS News WUXI, Jiangsu, China, Aug. 16 /PRNewswire-Asia-FirstCall/ -- China Wind Systems, (Nasdaq: Second Quarter 2010 Highlights and Recent Events]
[BIOSTAR PHARMACEUTICALS, SECOND QUARTER REVENUEREASED 46.4% TO $19.4 MILLION XIANYANG, China, August 17, 2010 - Q2 2010 revenuereased 46.4% to $19.4 million - Q2 2010 Non-GAAPjusted netomereased 50.9% to $5.8 million withjusted EPS of $0.21 - Biostar reiterates guidance for 2010: Revenue expected to be between $80.0 to $82.0 million and netome between $18.0 to]
[BIOSTAR PHARMACEUTICALS, SECOND QUARTER REVENUEREASED 46.4% TO $19.4 MILLION XIANYANG, China, August 17, 2010 - Q2 2010 revenuereased 46.4% to $19.4 million - Q2 2010 Non-GAAPjusted netomereased 50.9% to $5.8 million withjusted EPS of $0.21 - Biostar reiterates guidance for 2010: Revenue expected to be between $80.0 to $82.0 million and netome between $18.0 to]
